Trump Administration's MFN Drug Pricing Initiatives Impacting Medicare
The Trump Administration is actively pursuing "Most Favored Nation" (MFN) pricing for pharmaceuticals through executive actions and voluntary agreements. Currently, 16 drug manufacturers have agreed to apply MFN pricing, impacting primarily state Medicaid programs and cash-paying customers. However, the broader market effect appears limited.
In December 2025, the Centers for Medicare and Medicaid Services (CMS) introduced the GLOBE and GUARD models. These initiatives aim to incorporate international price comparisons into Medicare's drug rebate system for Part B and Part D, mandating manufacturer participation. The pilot programs will span six to seven years, covering around 25% of Medicare beneficiaries across selected regions.
Despite their potential, the implementation of GLOBE and GUARD faces uncertainty due to likely legal challenges under the Administrative Procedure Act. Concurrently, pharmaceutical manufacturers are adapting to immediate requirements from the Medicare Drug Price Negotiation Program, mandated by the Inflation Reduction Act (IRA), with compliance deadlines set for early 2026.
Engagement and Compliance
Stakeholders are encouraged to engage with CMS by providing feedback on the GLOBE and GUARD proposals before the February 23, 2026 deadline. Healthcare companies, including manufacturers and payers, should closely monitor these developments to assess potential impacts on regulatory compliance and business operations.
By late 2025, the Trump Administration announced agreements with 16 manufacturers to adhere to MFN pricing under the "Great Healthcare Plan," aiming to reduce drug costs for cash-paying consumers via platforms like TrumpRx. Despite these efforts, the arrangements predominantly affect state Medicaid programs and exclude traditional insurance plans.
The CMS's proposed GLOBE and GUARD models are experimental approaches designed to curtail Medicare spending, with GLOBE focusing on Part B and GUARD on Part D drugs. Initial implementation is not nationwide, and the projected federal savings could face legal scrutiny regarding mandatory participation and rebate computation.
Healthcare entities are advised to participate in the public comment period to influence these regulatory changes. Organizations should prepare for evolving regulations tied to the Medicare Drug Price Negotiation Program and comprehend how these may intersect with the proposed CMS models and prevailing legislative environments.